Leukocyte alkaline phosphatase and carcinoembryonic antigen in breast cancer patients: clinical correlation with the markers.
Leukocyte alkaline phosphatase (LAP) scores in peripheral blood and plasma carcinoembryonic antigen (CEA) levels were determined in 208 breast cancer patients with nonmetastatic disease. Patients were followed until clinical manifestations of metastases appeared. Then the LAP score and CEA level were analyzed in relation to the clinical appearance of metastases. Of the 208 patients studied, 58 developed metastases during the follow-up period. The LAP scores and CEA levels of this group of patients were compared to a control group of 60 breast cancer patients who did not develop metastases. Of the two markers, LAP score seems to be considerably more useful in detecting metastatic disease.
Walach
N
N
Department of Oncology, Assaf Harofeh Medical Center, Zerifin, Israel.
Guterman
A
A
Zaidman
J L
JL
Kaufman
S
S
Scharf
S
S
D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007962:Leukocytes / Q000201:enzymology; D008875:Middle Aged; D009362:Neoplasm Metastasis
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D000469:Alkaline Phosphatase